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Abstract 13 
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines 14 
(PCVs) to limit vaccine serotype (VT) prevalence. We aim to investigate if, consequently, the indirect protection 15 
of higher valency vaccines could fall short of the profound effects of current formulations.  16 
We compare three previously described pneumococcal models harmonized to simulate 20 serotypes with a 17 
combined pre-vaccination prevalence in <5y old children of 40%. We simulate vaccines of increasing valency by 18 
adding serotypes in order of their competitiveness and explore their ability to reduce VT carriage by 95% within 19 
10 years after introduction.  20 
All models predict that additional valency will reduce indirect vaccine effects and hence the overall vaccine 21 
impact on carriage both in children and adults. Consequently, the minimal effective coverage (efficacy against 22 
carriage * vaccine coverage) needed to eliminate vaccine type carriage increases with increasing valency. One 23 
model predicts this effect to be modest while the other two predict that high-valency vaccines may struggle to 24 
eliminate VT pneumococci unless vaccine efficacy against carriage can be substantially improved. Similar 25 
results were obtained when settings of higher transmission intensity and different PCV formulations were 26 
explored.   27 
Failure to eliminate carriage as a result of increased valency could lead to overall decreased impact of 28 
vaccination if the disease burden caused by the added serotypes is low. Hence a comparison of vaccine 29 
formulations of varying valency, and pan-valent formulations in particular, should consider the invasiveness of 30 
targeted serotypes, as well as efficacy against carriage.  31 
Background 32 
In 2000 the first pneumococcal conjugate vaccine (PCV), which provided protection against seven of the most 33 
pathogenic pneumococcal capsular serotypes, was licensed and recommended for immunization of infants in 34 
the US [1].  Subsequently, 10- and 13-valent formulations have been licensed and are now being used to 35 
prevent pneumococcal disease in more than 130 countries worldwide [2–11]. The incidence of carriage and 36 
disease associated with vaccine type serotypes (VT) declined in vaccinated children, and also in unvaccinated 37 
children and adults, after PCVs were introduced into national immunization programmes [12]. However, the 38 
overall prevalence of pneumococcal carriage remained approximately constant as non-vaccine serotypes 39 
(NVT), i.e., serotypes not targeted by the vaccine, filled the ecological niche [13]. The increased disease from 40 
these serotypes has partially offset the benefit of pneumococcal vaccination. As a result pneumococcal 41 
vaccines that target more or all serotypes are being developed [14].  42 
Previous work has suggested that the competition between vaccine type (VT) and non-vaccine type (NVT) 43 
serotypes plays an important role in the herd protection observed in the post PCV era [15–17]. In particular, by 44 
reducing acquisition of VT carriage, pneumococcal conjugate vaccines give NVTs a competitive advantage over 45 
VTs in the nasopharynx. Thus, in vaccinated populations the presence of NVT in vaccinated hosts provides 46 
additional competitive pressure, which combines with the immune protection afforded by the vaccine, to 47 
suppress VT colonization. Moreover, at the population level, there is competition between VT and NVT in non-48 
vaccinated hosts, and the spread of VT is likely inhibited by competition from NVT in non-vaccinated people as 49 
well. In each of these cases, the mechanisms of competition might include direct competition in the 50 
nasopharynx [18], induction of innate immune effectors by NVT that also inhibit VT [19], and induction of forms 51 
of acquired immunity that also inhibit VT, such as Th17-based and antibody-based immunity to conserved 52 
antigens [20–22]. For higher valent pneumococcal vaccines, including those that target proteins common to 53 
most pneumococci [14], this hypothesis implies that, by effectively losing the benefit of NVT competition, even 54 
with similar vaccine efficacy against pneumococcal carriage and disease, levels of indirect protection in 55 
unvaccinated individuals could fall short of the profound effects that have been observed with the routine use 56 
of conjugate vaccines.  57 
In this paper we explored three previously developed dynamic modelling approaches for pneumococcal 58 
ecology as to whether they predict a similar qualitative contribution of NVT competition to the indirect effects 59 
of pneumococcal vaccination.  We harmonized key model parameters that govern vaccine efficacy and 60 
pneumococcal epidemiology in the absence of vaccination and explored various vaccine scenarios to better 61 
understand the role of competition in providing protection. 62 
 63 
Methods 64 
Models 65 
The model by Bottomley et al [16] (M_B) is a deterministic model that represents the pre-PCV steady state of 66 
pneumococcal infections in the Gambia and was used to predict the impact of introduction of PCV13 into the 67 
childhood vaccination program. It is fitted to local longitudinal pre-vaccination carriage data. Serotypes are 68 
grouped into three classes of transmissibility (low, medium, high) and clearance rate (high, medium, low). 69 
Serotypes within the same group share the same properties. Pneumococcal carriers are assumed to gain partial 70 
immunity against acquisition of new serotypes during the episode of carriage, which represents the mechanism 71 
of serotype competition, and a proportion of clearances leads to life-long immunity against the cleared 72 
serotype, which balances competitive advantages to sustain serotype diversity. The default model 73 
parameterization is the same as reported in the original manuscript. 74 
The model by Cobey & Lipsitch [23] (M_CL) is an individual-based model that represents a generic high-income 75 
setting. Serotypes differed by their intrinsic duration of carriage and their in vivo competitive ability. 76 
Pneumococcal carriers are assumed to gain partial protection, quantified by the competitive ability of the 77 
resident type, against acquisition of additional serotypes during the episode of carriage, which represents the 78 
mechanism of competition. Following clearance, the host’s susceptibility to any subsequent homologous 79 
acquisition as well as the duration of any subsequent carriage episode is reduced. The strength of acquired 80 
immunity that reduces carriage duration was fitted to observations from a longitudinal carriage study in 81 
infants[24]. Acquired The serotype-specific immunity accentuates within-serotype competition thus providing 82 
balancing selection on serotypes, and acquired immunity independent of capsule reduces fitness differences. 83 
The simulations presented in this work rely on the default model parameterization, i.e. homogeneous mixing, 84 
the default rate of acquisition of capsular immunity (𝜎 = 0.3) and the default rate of acquisition of nonspecific 85 
immunity assuming non-linear reduction in carriage duration (𝜖 = 0.25). 86 
The model by Flasche et al [15] (M_F) is an individual based model that generalizes the most commonly used 87 
deterministic pneumococcal model [17,25,26]. It represents a generic high income country setting. Serotypes 88 
differ by their intrinsic duration of carriage. Duration of carriage and susceptibility to acquisition decline with 89 
age but are exposure independent. The acquisition of a pneumococcus triggers both a transient homologous 90 
immune response, which represents serotype competition, and a transient heterologous immune response, 91 
which represents the mechanism to ensure serotype coexistence. Both immune responses are assumed to 92 
prevent additional acquisition of respective serotypes. Unless mentioned otherwise the simulations presented 93 
in this work rely on the default model parameterization, i.e. the duration of specific and non-specific immunity 94 
was 9 and 18 weeks respectively.  95 
While there was no formal model selection process we included models that span most of the range of 96 
alternative dynamic pneumococcal model assumptions on serotype competition and natural immunity (ie M_F 97 
includes most deterministic modelling approaches to date). An overview of the different modelling approaches 98 
in this study is shown in Table 1. The main differences between models in regards to this work are the 99 
assumptions on acquired immunity and the resulting mechanisms for competition and serotype coexistence.  100 
 101 
Analyses 102 
We harmonized models to simulate 20 artificial serotypes with a combined pre-vaccination prevalence in <5y 103 
old children of 40%, approximating a high income setting with moderate transmission, or 70%, approximating a 104 
low income setting with high transmission intensity. In M_B serotypes were evenly distributed between the 105 
three classes, i.e. 7, 7,6 serotypes of low, mid and high transmission intensity. For each model, parameters 106 
governing transmission intensity were scaled to achieve the desired prevalence. In M_F changing the 107 
transmission intensity alone was insufficient to achieve the targeted 70% prevalence (compare discussion in 108 
Flasche et al [15]). Hence, once the effects of increasing the transmission intensity saturated it was kept 109 
constant and the duration of specific and non-specific immunity were subsequently decreased to 6 and 12 110 
weeks respectively to achieve the targeted prevalence. As M_B was not age structured we split all 111 
compartments into an <5y old and a 5 years and older compartment retaining all original parameters and 112 
constant rate of transition between the strata such that the mean time spent in the <5 stratum was 5 years. To 113 
minimize the effects of stochasticity M_CL was run 10 times and mean values are presented. Stochastic 114 
variability on presented outcomes was too small to visualize in the Figures so it was omitted. The Simpson 115 
Index was calculated as a measure of serotype diversity [27].   116 
We explored two vaccines with alternative compositions each. Firstly, we compared generic vaccines of 117 
increasing valency where serotypes are included in order of their competitiveness. Serotype “1” is the 118 
strongest competitor, indicated in all models by the highest prevalence in the pre vaccine era, and “20” the 119 
lowest. Note that the serotype names do not correspond to the numbering conventionally used for 120 
pneumococcal serotypes. Secondly, to approximate PCV7, PCV10, PCV13 and PCV15 we modelled inclusion of 121 
serotypes into the vaccine in respect to their observed paediatric prevalence rank among carriage globally. For 122 
example PCV7 targets serotypes 4,6B,9V,14,18C,19F and 23F which are the 18th, 2nd, 6th, 5th, 11th, 1st, 3rd most 123 
prevalent serotypes globally; hence the PCV7-like vaccine in this work targets model serotypes 1,2,3,5,6,11 and 124 
18 (Table 2) [28]. Serotypes of a lower rank than 20 were not included since the models only consisted of 20 125 
serotypes.  126 
M_B and M_F assume that both immunity, including vaccine induced immunity act as all-or-nothing while the 127 
Cobey and Lipsitch model assumes it is leaky. The models were run to predict 1) the impact of vaccination 128 
against each targeted serotype [29] (assuming 100% coverage and 55% efficacy) and 2) the effective coverage 129 
needed to achieve elimination of VT carriage.  We defined effective coverage as vaccine efficacy times vaccine 130 
coverage (N.B. in the two models that assume all-or nothing vaccine protection this is equivalent to the fraction 131 
of the population that is protected by vaccination, in the M_CL we assumed 100% population coverage and 132 
varying vaccine efficacy), and elimination of VT carriage as a reduction of VT carriers of 95% or more. The 133 
impact of vaccination is measured as either the percentage reduction in the number of VT carriers, or 134 
alternatively with any serotype, in year 10 after the start of vaccination if compared to the year before 135 
vaccination (steady state). We choose to report only the impact after 10 years as for this work we were only 136 
interested in potential qualitative differences in predictions in the mid to long term of vaccine introduction.  137 
 138 
 139 
Results 140 
Models differed in the proportion of children among the simulated population. M_B assumed an age 141 
distribution based on the Gambia and hence that children younger than 5 years old make up 20% of the total 142 
population. In both other models that represent high income countries the corresponding proportion was 5% 143 
(Figure 1). Pneumococcal carriage prevalence was almost evenly distributed across serotypes in M_F and 144 
dominated by fewer serotypes in M_CL. The Simpsons index in children was 0.871, 0.845, 0.885 in the 145 
moderate transmission scenario for M_B, M_CL and M_F and 0.925, 0.862, 0.927 in the high transmission 146 
scenario. The models differed how the targeted prevalence in children translated into prevalence in older 147 
individuals (Figure 1). Carriage prevalence decreases with age except for M_B which was originally designed to 148 
be age independent and hence uses the same parameters for both age groups.  149 
In the moderate transmission scenario, the vaccine impact against vaccine type carriage 10 years after the start 150 
of vaccination of a vaccine with 55% effective coverage decreased with increasing vaccine valency in all three 151 
models (Figure 2). The effect of including more VTs was least visible in M_CL where only inclusion of almost all 152 
serotypes (15 or more) reduced the impact on VT carriage to allow VT circulation. The M_B predicted the 153 
steepest decrease in vaccine impact on VT prevalence as a result of inclusion of highly and moderately 154 
competitive serotypes, however, further inclusion of weakly competitive serotypes which were hardly carried 155 
in this scenario did not change the impact of vaccination. Similar dynamics were observed for older individuals 156 
and the high transmission scenario, however, M_F predicted a small initial increase in vaccine impact on VT 157 
carriage before the impact decreased for higher valencies.  158 
The impact of vaccination on all serotype carriage measured 10 years after the start of vaccination with a 159 
vaccine with 55% effective coverage generally increased with increasing valency. However, for the high 160 
transmission scenario M_CL predicted a negative vaccine impact, i.e. an increase in overall pneumococcal 161 
carriage through the inclusion of almost all serotypes into the vaccine formulation and only for valencies of 19 162 
and higher predicted a positive impact of vaccination, i.e. a reduction in all serotype carriage prevalence.  163 
The PCV7-like and PCV10-like as well as the PCV13-like and PCV15-like vaccines were indistinguishable because 164 
the global prevalence rank of the respectively added serotypes were larger than the number of serotypes 165 
considered in this analysis and hence omitted. All three models predict that the impact of vaccination against 166 
pediatric VT carriage is similar (<5% difference) across the PCV-like formulation (Figure 3). However, changes in 167 
vaccine impact on carriage with any serotype were more pronounced but followed the dynamics of the generic 168 
vaccine; i.e. inclusion of more serotypes further reduced carriage prevalence, except in M_CL in the high 169 
transmission scenario. 170 
Consistent with the effect of increasing valency on vaccine impact, increasing the valency of the generic vaccine 171 
formulation was predicted to increase the effective coverage needed to eliminate VT carriage in both children 172 
and older individuals and in both moderate and high transmission intensity settings (Figure 4). In all three 173 
models VT elimination in the general population required less than 10% additional effective coverage to 174 
elimination VT carriage among children. In contrast to the other models M_CL predicted that addition of up to 175 
half of all serotypes into the generic vaccine formulation would not have a profound effect on the effective 176 
coverage needed for elimination of VT carriage but that only inclusion of at least 10 serotypes or 15 serotypes 177 
in the moderate and high transmission scenario respectively would. Elimination of pneumococci using a pan-178 
valent vaccine was impossible in M_F and also for the high transmission scenario in M_B. 179 
For PCV-like vaccines a similar qualitative behavior to the generic vaccine formulations was predicted. The 180 
three models predicted that the effective coverage needed to eliminate VT carriage in the population increases 181 
by 12, 2 and 11% respectively for the moderate transmission intensity setting if a PCV13 or 15 – like vaccine 182 
was used instead of a PCV7 or 10 – like vaccine. In the high transmission intensity setting elimination of VT 183 
carriage for the two modelled vaccine formulations was impossible in M_F, required effective coverage larger 184 
than 88% and 97% in M_B and required effective coverage of 34% and 37% in M_CL. 185 
 186 
Discussion 187 
Pneumococcal conjugate vaccines have substantially reduced the burden of pneumococcal disease worldwide. 188 
However, through replacement with serotypes not targeted by the vaccines a sizeable burden remains and has 189 
led to ongoing development of vaccines with higher valency. Using qualitative results across three 190 
pneumococcal models that span a variety of assumptions on the acquisition of pneumococcal immunity and 191 
serotype competition, we here show that serotype competition from NVTs aids VT elimination. Accordingly, we 192 
show that targeting an increasing number of serotypes increases the requirements on vaccine efficacy and/or 193 
vaccine coverage to achieve elimination of VT carriage. We predict that the relatively small differences in the 194 
number of serotypes targeted by current PCV formulations are unlikely to be substantial enough to lead to 195 
measurable differences in the ease of VT elimination but that vaccines that target almost all serotypes may 196 
allow continued circulation of the most competitive serotypes even if such vaccine was given at high coverage 197 
and the vaccine efficacy against carriage was improved over the efficacy of PCVs. 198 
Given the qualitative nature of this comparison we have only assessed the impact of vaccine valency on the 199 
potential of elimination of pneumococcal carriage. The implications of the results for the disease impact of a 200 
switch from current PCV formulations to a pan valent vaccine are complex. Increasing vaccine valency could 201 
lead to a net increase in pneumococcal disease burden if the highly competitive serotypes are controlled only 202 
through a vaccine with limited valency and are also highly pathogenic while the types not targeted by the 203 
formulation with limited valency rarely cause disease. In this case, the small disease benefit of controlling more 204 
serotypes could be outweighed by the increased circulation of the serotypes in the limited-valency vaccine. The 205 
expansion of PCV formulations thus far to incorporate additional serotypes responsible for significant amounts 206 
of disease has tended to emphasize highly invasive serotypes, thereby minimizing the potential problem we 207 
highlight for expansions of the valency of PCVs.  A recent study suggests a method for such that would continue 208 
this beneficial approach [30]. 209 
In vaccinated persons, these unintended effects might be fully or partially offset through the additional direct 210 
vaccine protection against disease, given that PCV formulations thus far have provided >80% protection against 211 
disease, with lower efficacy against carriage [29,31–33]. This implies that unintended effects of increased 212 
valency of vaccines might be of greatest concern – and thus most deserving of surveillance – in age groups 213 
within a population that have not been vaccinated, such as healthy adults in most countries at present. We 214 
emphasize that the model-comparison exercise here was designed to assess general trends in the behaviors of 215 
the models, rather than to predict specifically how a higher-valency vaccine would act in a particular 216 
population. Setting-specific model parameterization is required to allow quantification of the differential 217 
impact of vaccine of varying valency on pneumococcal disease. 218 
We show that the observation that serotype competition aids VT elimination and hence that increasing the 219 
valency of pneumococcal conjugate vaccine is likely to increase the herd immunity threshold is insensitive to 220 
different assumptions of peadiatric carriage prevalence and vaccine formulation which we consistently 221 
explored across all three models. Most importantly we show that this finding is also insensitive to alternative 222 
model assumptions of pneumococcal ecology, the mechanisms of between serotype competition and 223 
differences in underlying demographics.  224 
We made the simplifying assumption that serotype specific direct vaccine effects are the same across vaccines 225 
and targeted serotypes and that they follow those of current PCV formulations; i.e. an approximate 55% 226 
efficacy against carriage acquisition of any targeted serotype [29]. However, because of the complexities 227 
involved in the conjugation procedure of PCVs it is unlikely that using current techniques PCVs will be able to 228 
target more than 20 of the over 90 pneumococcal serotypes [34]. Vaccines that target common proteins rather 229 
than specific capsules on the other hand may prevent pneumococcal disease by different mechanisms, e.g. 230 
enhanced IL-17A mediated nasopharyngeal clearance rather than prevention of acquisition [35]. While 231 
inference of the differential population impact of specific pneumococcal vaccines would require a more precise 232 
parameterization including the focus on a specific setting, the qualitative results of this work are likely to 233 
similarly apply. 234 
In a few instances the models predicted changes to pneumococcal ecology following vaccination that seem 235 
counter-intuitive at first. In the high transmission scenario, M_CL predicted that overall pediatric carriage 236 
prevalence would stay relatively constant (less than 5% change) for vaccines that included up to 8 of the most 237 
competitive serotypes, but then increase by up to 40% if more serotypes were targeted by the vaccine to finally 238 
reduce overall carriage by targeting at least 19 serotypes (Figure 2). This is unique to this model because of its 239 
inclusion of a gradient in type-specific ability to prevent additional acquisition: carriers of highly-competitive 240 
serotypes are more protected against acquisition of further serotypes. By protecting against the most 241 
competitive serotypes through vaccination the remaining serotypes are under less pressure from competition 242 
to a point where they act almost independently. For vaccines that target between 9 and 18 of all serotypes in 243 
the high transmission setting the prevalence of untargeted serotype in the virtual absence of competition then 244 
adds up to exceed the overall prevalence before vaccination (Appendix Figure 1). Furthermore, in M_CL the 245 
impact of vaccination with low valency vaccines is similar in both transmission settings but higher for moderate 246 
to high valency vaccines in high transmission settings than in moderate transmission settings. In contrast, most 247 
models including M_B and M_F predict that transmission intensity and the herd immunity threshold are always 248 
positively correlated [36]. In M_CL that same effect is evident only for vaccines that target all serotypes. For 249 
vaccines that target most but not all pneumococci this model predicts that the relatively weak competitive 250 
pressure from NVTs in combination with a substantial increase in overall pneumococcal prevalence in high 251 
transmission scenarios helps to control VT circulation better than vaccination in a moderate transmission 252 
scenario with less transmissible VTs but also lower NVT carriage prevalence that compete with VTs. M_F 253 
predicted that, assuming 55% effective coverage in the high transmission scenario, increasing the valency to up 254 
to 15 serotypes leads to a small increase in vaccine impact on VT carriage which is qualitative different from all 255 
other models and scenarios presented here. This is a result of comparing the impact of vaccination on a 256 
different number of serotypes. In particular, reduction in carriage prevalence of e.g. serotype “1” as a result of 257 
vaccination in the high transmission scenario steadily declines with increasing valency in M_F (Figure 2). 258 
However, the indirect effect of vaccination against serotypes of lower prevalence is greater and hence 259 
comparing the impact of vaccination on all vaccine serotypes includes both the counter-acting trends. Only in 260 
the high transmission setting in M_F is a net increase in vaccine effects against VTs predicted for low valency 261 
vaccines. 262 
While the models agree well on the qualitative relation between vaccine valency and the herd immunity 263 
threshold we have observed stark differences in the quantitative results. For example M_CL predicted that 264 
much lower effective coverage is required for elimination of VT carriage. Many factors contribute to this 265 
observation and some could be addressed by more detailed harmonization of the models to a specific setting. 266 
However, two intrinsic model assumptions likely drive this behavior: 1) the strength of vaccine protection and 267 
2) the strength of serotype competition. M_CL assumes a relatively strong vaccine protection by reducing 268 
susceptibility to VT acquisition permanently after vaccination. M_F assumes vaccine protection, albeit non-269 
leaky, to only hold for 10 years while M_B also assumes lifelong protection from vaccination, although 270 
modelled as all-or-nothing and hence even stronger than in M_CL. While the evidence suggest PCVs to be leaky 271 
[37] little is known about upcoming pan-valent vaccines. Vaccine protection has been found to remain present 272 
5 years after completion after childhood immunization [38] but there is some evidence that protection declines 273 
over time albeit with a half-life that exceeds 5 years [29]. Further, M_CL has the weakest serotype competition 274 
of the models by assuming leaky protection against heterologous acquisition of additional colonizing strains 275 
during carriage with the most competitive serotypes providing stronger protection against new acquisition. In 276 
comparison M_B and M_F respectively assume competitive exclusion on acquisition and potential co-infection 277 
but only after non-leaky heterologous immunity following acquisition has ended. With the relatively weak 278 
competition of serotypes in M_CL a targeted pediatric carriage prevalence is achieved with lower transmission 279 
intensity and this in turn will ease elimination of vaccine serotypes in comparison to the other models where 280 
transmission is more intense. Recent advances in molecular serotyping methods have shown the pneumococci 281 
frequently co-colonise [39,40] and while epidemiological studies suggest that carriage induces both 282 
homologous and heterologous protection such protection from a single episode of carriage likely is relatively 283 
weak [20,41,42].  284 
 285 
Conclusion 286 
Using three different modelling approaches for pneumococcal ecology that represent a range of alternative 287 
assumptions on pneumococcal immunity and serotype competition we found that NVT competition helps 288 
vaccines of limited valencies eliminate VT carriage. This implies that new vaccines that targeted the majority of 289 
pneumococcal serotypes will benefit less from NVT competition and are likely to offer less indirect protection 290 
than current PCVs. Head to head comparison of current PCVs with high-valency vaccines should not only be on 291 
the grounds of non-inferiority of direct effects but should also account for indirect effects, and closely monitor 292 
IPD endpoints. 293 
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 435 
Tables and Figures 436 
Table 1: Summary of the main features of each model of pneumococcal transmission 437 
 
Bottomley et al Cobey & Lipsitch Flasche et al 
Model type Compartmental Individual based Individual based 
Demographics Gambia High income country  High income country 
Mixing patterns Homogeneous Homogeneous Age-assortative 
Natural 
immunity as a 
result of 
infection 
non-specific: transient immunity 
for the duration of infection 
anticapsular: chance to develop 
permanent homologous immunity 
non-specific: permanent increase 
in clearance rate, transient 
reduction in acquisition rate for 
the duration of infection 
anticapsular: permanent 
reduction in susceptibility to 
homologous infection 
non-specific: transient immunity 
to heterologous infection 
anticapsular: additional transient 
immunity to homologous 
infection 
other: exposure independent 
reduction of susceptibility and 
carriage duration with age 
Vaccine induced 
immunity 
Like anticapsular natural 
immunity but higher chance for 
protection 
Like anticapsular natural 
immunity but stronger protection 
Like anticapsular natural 
immunity but longer protection 
 438 
Table 2: PCV formulations and the ranks of each serotype in terms of its global prevalence according to a 439 
review on the global distribution of paediatric pneumococcal carriage 440 
 
Serotypes (rank) 
PCV7 4 (18), 6B (2), 9V (6), 14 (5), 
18C (11), 19F (1), 23F (3) 
PCV10 + 1 (31), 5 (38), 7F (32) 
PCV13 + 3 (9), 6A (4), 19A (7) 
PCV15 + 22F (27), 33F (24) 
 441 
Fig. 1 Model demographics and serotypes distribution before the introduction of vaccination. Upper panel: The 442 
cumulative age distribution of the model populations.  Lower panel: a stacked barplot to illustrate the 443 
predicted serotype distributions (stacked prevalence of serotype specific carriage episodes scaled to the overall 444 
carriage prevalence) in children and the rest of the population in low and high transmission settings.  445 
Fig. 2: Predicted percentage reduction in the prevalence of pneumococcal carriage (bottom row), VT carriage 446 
(middle row) and carriage of the most competitive serotype (top row) 10 years after vaccine introduction, 447 
assuming 55% efficacy against acquisition of pneumococcal VTs and 100% coverage.  448 
Fig. 3: Percentage reduction in the prevalence of pneumococcal carriage 10 years after introduction of a PCV 449 
like vaccine, assuming 55% efficacy against acquisition of pneumococcal VTs and 100% coverage.  450 
Fig. 4: The effective coverage needed to prevent 95% of VT carriage 10 years after the start of vaccination, 451 
assuming serotypes are added to the vaccine in order of their carriage prevalence. At valency 7 and 10 the 452 
respective effective coverage for PCV7/10 – like and PCV13/15 – like vaccines are indicated by large dots and 453 
triangles in respective colors. 454 
 455 
Appendix 456 
Appendix Figure 1: The proportion of carriers that carry 1,2...,6 pneumococci at a time following ten years of 457 
vaccination. Rows show different models and columns different transmission intensities indicated by the 458 
prevalence of carriage in less than 5-year-old children before vaccination. In M_B each host can only carry one 459 
pneumococci at a time and hence the model is not represented here. 460 
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